Cargando…

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma

BACKGROUND: RAS effector signaling pathways such as PI3K/mTOR and ERK are frequently dysregulated in glioblastoma. While small molecule targeted therapies against these pathways have appeared promising in preclinical studies, they have been disappointing in clinical trials due to toxicity and de nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreck, Karisa C, Allen, Amy N, Wang, Jiawan, Pratilas, Christine A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668446/ https://www.ncbi.nlm.nih.gov/pubmed/33235998 http://dx.doi.org/10.1093/noajnl/vdaa138

Ejemplares similares

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
por: Yamashita, Alex Shimura, et al.
Publicado: (2020)

Heterogeneity and excitability of BRAF(V600E)-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss
por: Cases-Cunillera, Silvia, et al.
Publicado: (2021)

Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
por: Chang, Raymond, et al.
Publicado: (2019)

EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling
por: Wei, Yutian, et al.
Publicado: (2020)

BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma
por: Gusyatiner, Olga, et al.
Publicado: (2021)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors
por: Meel, Michaël H, et al.
Publicado: (2020)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage
por: Vasheghani, Faezeh, et al.
Publicado: (2015)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
por: Pratap, Uday P, et al.
Publicado: (2021)

Multireceptor targeting of glioblastoma
por: Sharma, Puja, et al.
Publicado: (2020)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models
por: Conage-Pough, Jason E, et al.
Publicado: (2023)

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022)

Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors
por: Knudsen, Arnon Møldrup, et al.
Publicado: (2021)

Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma
por: Woodall, Ryan T, et al.
Publicado: (2021)

Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile
por: Hägerstrand, Daniel, et al.
Publicado: (2011)

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma
por: Neirinckx, Virginie, et al.
Publicado: (2019)

Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma
por: Badodi, Sara, et al.
Publicado: (2022)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies
por: Houweling, Megan, et al.
Publicado: (2023)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

CRN2 enhances the invasiveness of glioblastoma cells
por: Ziemann, Anja, et al.
Publicado: (2013)

GammaTile® brachytherapy in the treatment of recurrent glioblastomas
por: Gessler, Dominic J, et al.
Publicado: (2021)

Expression of pluripotency-related genes in human glioblastoma
por: Rios, Álvaro Fabrício Lopes, et al.
Publicado: (2021)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas
por: Abou-El-Ardat, Khalil, et al.
Publicado: (2017)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults
por: Huang, Ruoyu, et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

NCoR controls glioblastoma tumor cell characteristics
por: Heldring, Nina, et al.
Publicado: (2014)

Sprouty2 enhances the tumorigenic potential of glioblastoma cells
por: Park, Jong-Whi, et al.
Publicado: (2018)

Proteins inform survival-based differences in patients with glioblastoma
por: Stetson, L C, et al.
Publicado: (2020)

The invasive proteome of glioblastoma revealed by laser-capture microdissection
por: Daubon, Thomas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dc40f3jliko9nnusi96a4frfhl